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Abstract
The causes and etiology of Crohn’s disease (CD) are currently unknown although both host genetics and environmental
factors play a role. Here we used non-targeted metabolic profiling to determine the contribution of metabolites produced
by the gut microbiota towards disease status of the host. Ion Cyclotron Resonance Fourier Transform Mass Spectrometry
(ICR-FT/MS) was used to discern the masses of thousands of metabolites in fecal samples collected from 17 identical twin
pairs, including healthy individuals and those with CD. Pathways with differentiating metabolites included those involved in
the metabolism and or synthesis of amino acids, fatty acids, bile acids and arachidonic acid. Several metabolites were
positively or negatively correlated to the disease phenotype and to specific microbes previously characterized in the same
samples. Our data reveal novel differentiating metabolites for CD that may provide diagnostic biomarkers and/or
monitoring tools as well as insight into potential targets for disease therapy and prevention.
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Introduction
Crohn’s disease (CD) is an inflammatory bowel disease (IBD),
characterized by chronic inflammation of the gastrointestinal tract.
The exact etiology of CD is unknown, but both the host genotype
and environmental factors play a role, and it is known that disease
induction requires the presence of bacteria. No specific pathogen
has been defined as a causative agent, but individuals with CD
have an imbalance or ‘dysbiosis’ of their intestinal microbiota, or
microbiome [1], [2]. Dysbiosis in turn leads to a breakdown in the
de ´tente relationship between the microbiome and the host
immune system, through unknown mechanisms.
Diagnostic and monitoring tools for CD are currently
inadequate. Numerous serological biomarkers have been proposed
for the diagnosis of CD. However, for clinical applications, none of
the current markers stand-alone and they are therefore used in
conjunction and as a supplement to endoscopy. Therefore, more
accurate tools are needed for early diagnosis of CD; in particular
non-invasive approaches that can be used in place of endoscopy.
Our aim was to search for metabolic biomarkers of CD as
evidence of microbial functions in the gut. Recent advances in
nuclear magnetic resonance (NMR) and mass spectrometry (MS)
have made it possible to simultaneously assess thousands of
metabolites corresponding to the ‘‘metabolome’’ and to determine
end-points of metabolic processes in living systems [3]. NMR (
1H
NMR Spectroscopy) has revealed gut microbial contributions to
metabolite compositions in different body fluids, including blood
[4], urine [5], [6] and fecal extracts [7], [8]; and the latter has
revealed some metabolites that are correlated to CD [7].
Although the information provided using NMR has been very
valuable it is still limited by low resolution and sensitivity that only
enables the annotation and quantification of a limited number of lower
molecular weight molecules. By contrast, ion cyclotron resonance-
Fourier transform mass spectrometry (ICR-FT/MS) with an ultrahigh
mass resolution enables differentiation of very subtle variations in
thousands of mass signals, including higher molecular weight
metabolites [9]. The combination of coupled metabolite separation
technologies to spectrometry and spectroscopy enables a multidimen-
sional approach for the structural identification of new metabolites as
recently exemplified for markers of diabetes and early stage insulin
resistance [10]. Therefore, in this study we used ICR-FT/MS with its
high dynamic range and high mass accuracy (0.2 ppm) to obtain non-
targeted profiles of elementary compositions in fecal samples obtained
from individuals with CD.
Analysis
Patient cohort
The selection criteria and patient information for the twins
studied in this experiment have previously been described [11],
PLoS ONE | www.plosone.org 1 July 2009 | Volume 4 | Issue 7 | e6386[12]. Patient information presented in Table S1, including
responses to a questionnaire regarding the usage of antibiotics,
non-steroidal anti-inflammatory drugs during the preceding 12
months, gastroenteritis within the preceding 3 months, and specific
dietary habits have previously been reported [12]. Written
informed consent was obtained and approved by the Swedish
ethical committee. The sample cohort was comprised of 15 twin
pairs, with 7 healthy twin pairs, 4 pairs that were discordant for
predominantly colonic CD (CCD), 2 pairs that were discordant for
predominantly ileal CD (ICD), 2 pairs that were concordant for
ICD, and 2 pairs that were concordant for CCD. There were a
total of 8 individuals with CCD (aged 20–70, mean 48), 6
individuals with ICD (aged 44–53, mean 49.8), 6 healthy
individuals with a sick twin (HD) (ages 20–70, mean 51.8) and
14 healthy individuals with a healthy twin (HH). In the HH group,
5 pairs were children (ages 5–11, mean 7.4) and 2 pairs were of
similar ages to diseased individuals (45–55 mean 50). All diseased
individuals were in clinical remission according to the Harvey-
Bradshaw score [13] with the exception of 2 individuals (10b and
15a). Both of these individuals had endoscopic recurrence scores
below 2 [14] at colonoscopy suggesting that the Harvey-Bradshaw
score did not indicate active CD. Fecal samples were placed in a
freezer at 270 uC within 24 h of collection, until analysis. The use
of human subjects for this study was approved by the O ¨ rebro
County Ethical Committee (Dnr; 167/03).
Preparation of fecal water
Fecal samples were diluted 1:60 (weight:volume) in cold (4uC)
50 mM sodium phosphate buffer (pH 8.0). The suspension was
mixed in a gyratory shaker at 120 rpm for 10 min at 4uC and then
centrifuged at 200 x g for 10 min at 4uC to pellet the debris. The
supernatant was removed and centrifuged at 18,000 x g for
10 min to pellet the bacteria. The supernatant was collected and
the pH was lowered to approximately 4.5 by addition of 0.25 mL
of 1% formic acid to each mL of supernatant, with a resulting final
sample dilution of 1:75. The fecal water samples were frozen and
stored frozen at 270uC until analysis. The samples were extracted
20 min after they were thawed at room temperature by solid phase
extraction (SPE) using 1 L cartridges filled with 100 mg of
octadecy-bonded silica packing (Bakerbond, Mallinckrodt Baker,
Griesheim, Germany) for desalination and deproteination of the
sample. The cartridges were preconditioned with 2 mL of
methanol and 2 mL of water acidified with 0.1% formic acid
prior to the application of 0.5 mL of sample. The columns were
washed with 0.5 mL of 0.1% formic acid and metabolites were
eluted with 0.5 mL methanol.
FT-ICR-MS analysis
High-resolution mass spectra (resolution D(m/z)/(m/z) of
500.000 at m/z 500 in full scan mode) were acquired on a
Fourier Transform Ion Cyclotron Resonance Mass Spectrometer
(Bruker, Bremen, Germany), equipped with a 12 Tesla supercon-
ducting magnet and an Apollo II ESI source. Samples were
infused with the micro-electrospray source at a flow rate of
120 mL/h with a nebulizer gas pressure of 20 psi, and a drying gas
pressure of 15 psi at 250uC. Negative and positive electrospray
ionisation was used. Spectra were externally calibrated on clusters
of arginine (m/z of 173.10440, 347.21607, 521.32775 and
695,43943) dissolved in methanol at a concentration of 10 mg/
L; calibration errors in the relevant mass range were always below
0.1 ppm. Four MW time domains were applied in the mass range
of 150–2000 m/z. The ion accumulation time in the ion source
was set to 2 s and 200 scans were accumulated per sample. Before
Fourier transformation of the time-domain transient, a sine
apodization was performed. The raw data were processed with
DataAnalysis 3.4 (Bruker Daltonik, Bremen) software that is hard-
coded in the instrument. Peaks exceeding a threshold signal-to-
noise ratio of 3 were exported to peak lists. The extracted spectra
were aligned though in-house software.
Identification of differentiating masses and assignment
to metabolic pathways
Different multivariate analysis techniques including principal
component analysis (PCA), hierarchical cluster analysis (HCA) and
partial least square discriminant analysis (PLS-DA) were combined
to reduce the data sets into a series of optimized and interpretable
objects. The study of contribution of the different variables (m/z in
this case) was done though the analysis of the regression
coefficients. The statistical analyses were done with SIMCA-P
11.5 (Umetrics, Umea, Sweden), SAS version 9.1 (SAS Institute
Inc., Cary, NC, USA) and the Statistical package ‘‘R’’ (v 1.8.1) for
the heatmap visualization.
The masses with the highest regression coefficient (an arbitrary
cut off value .0.0004) were chosen to be discriminant. Moreover
these masses have a variable importance in the projection VIP.1
(where a VIP value of $1 is regarded as significant). The VIP is a
computation of the influence of every x term in the model on the y
variable (ICD, CCD, and Healthy). Larger VIP values indicate a
greater influence of a term x on the y variable.
We used a PLS-DA model to evaluate the m/z that contributed
to separation between healthy vs individuals with CCD and ICD.
The model gave good values for Q
2(cum)=0.6 and R
2(Y)=0.9.
However the permutation test applied with 100 permutations
revealed a possible over fitting of the model. Thus the dataset was
reduced excluding the masses with frequencies less than three and
a PLS model with an orthogonal signal correction (OSC) was
applied. The putative masses responsible for the metabolic
differentiation were used to make queries in the KEGG database
(Kyoto Encyclopedia of Genes and Genomes) through the
MassTRIX software [15] including Homo sapiens and Bacteroides
vulgatus as reference species. MassTRIX calls the KEGG/API
(http://www.genome.jp/kegg/soap/) to generate pathway maps,
where the annotated compounds and genes are highlighted using
different colors-thus differentiating between organism-specific and
extra-organism items [15]. The identification of certain metabo-
lites as their exact masses in their given biological context was
strategic in the context of searching for biomarkers for CD.
Correlation of metabolites to microbial profiles
The bacterial community profiles of the same fecal samples
studied here have previously been reported [12]. To determine
correlation between the microbial community composition and the
metabolic profiles, distance matrices using Manhattan distances
[16] for microbial and metabolic profiles were calculated indepen-
dently, then Pearson correlation coefficients between the two
distance matrices were calculated. Significances of the correlations
were tested using the Mantel test with 1000 permutations. Cluster
analysis of microbial and metabolic profiles was performed using
binary data (Jaccard’s similarity index). Moreover the relation
between the metabolites and the microbial profiles was analyzed
with a PLS model with OSC, the metabolites were used as
explicative variables. The relation of the first ten explicative masses
with the different bacteria was expressed with the heatmap.
Discussion
Due to the tremendous individual diversity in the composition
of the gut microbiota in humans and the corresponding
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it to be challenging to correlate specific metabolites to CD.
Therefore, in this study, we focused on a twin cohort, described
previously [2], [17], that includes healthy twin pairs, concordant
pairs (both twins have CD) and discordant pairs (one twin is
healthy and the matched twin has CD). The patients with CD
were further differentiated depending on whether inflammation
was primarily localized in the ileum (ICD) or in the colon (CCD)
[2], [17]. A particular value of this patient cohort was the
availability of existing data about the microbial profiles in fecal
samples [17] and biopsies [2] from the same individuals that
enabled the possibility of correlation of metabolites to microbial
populations. Our previous studies showed that there were
significant differences in levels of several members of the microbial
communities in the gut of individuals that had ICD compared to
those with CCD or to healthy individuals; in particular
dramatically lower abundances of Faecalibacterium prasnitzii and
higher levels of Escherichia coli in individuals with ICD compared to
the other two groups [2]. However, there was no clear distinction
between the microbial community profiles in healthy individuals
and those with CCD. Although the gut microbial communities of
healthy twins were more similar to each other than to other
individuals in the sample cohort, this similarity was no longer
evident when comparing twin sets where one or both twins were
sick [17].
In this study, we used several multivariate statistical approaches
to analyze the metabolites present in the liquid phase (fecal water)
of the same fecal samples examined earlier [17]. First, using
principal components analysis (PCA) we found that the metabo-
lomes of individuals that had ICD grouped separately from those
with CCD and from healthy individuals (Figure S1). Some of the
healthy individuals were young (Table S1) and their metabolomes
grouped separately from the healthy adults on the PCA plots
(Figure S1). This distinction between healthy young and old was
not evident in our previous analyses of the microbial community
compositions [17]. An example of a discriminating metabolite that
contributed highly to the grouping of the young was 5b-
cyprinosulfate, a bile acid that was more abundant in young
subjects (P,0.003) compared to all other groups. Because there
were no young individuals with CD in this study, we continued
with adults only for further statistical discrimination of diseased
from healthy groups.
Using a partial least squares (PLS) statistical approach on
corrected mass data the separation between disease phenotypes
was even more pronounced than when using the PCA model, with
a clear separation of individuals with ICD from those with CCD
and from healthy individuals (Fig. 1A) and some examples of
differentiating metabolites are shown in Figure 1B. This
differentiation according to disease phenotype that was seen using
both the PCA and PLS approaches provides further support to the
recent hypothesis that ICD and CCD are different disease
phenotypes of CD. The outlier with CCD was the youngest of
our Crohn’s patients (born 1986) and had only had the disease for
4 years at the time of sampling, whereas all the others have had the
disease for .10 years.
The 2
nd component of the PLS model also revealed a clear
separation, not only between the individuals with ICD versus
CCD and healthy, but also between CCD and healthy. These data
are the first that we have seen from this sample cohort that
differentiate healthy from CCD individuals. Therefore, the
resolution of separation of the groups was higher for the
metabolite profiles than for the microbial community profiles
[17], thus demonstrating the potential for use of metabolomics as
an approach for accurate disease diagnosis. One reason for the
higher discrimination of the metabolite data compared to the
microbial data could be the direct link of metabolites to function
since they represent the final signature of enzymatic processes
occurring in the gut. By comparison, detection of microbial
presence based on DNA targets may be misleading since many
species in the gut may be dormant, dead, or transient and this
information is not available when assessing DNA alone. Another
explanation for the difference between DNA-based surveys and
metabolite-based surveys could be that some microbes may be
present and active in both diseased and healthy individuals, but
may not have a significant effect on levels of the metabolites that
we are screening for.
Metabolites within a broad range of pathways contributed to
the differentiation of healthy from diseased individuals, as well as
between disease phenotypes (Fig. 2A, Table 1). From the total
number of 18,706 measured masses, we found that 7919 were
discriminating for a specific disease phenotype: 2155 for ICD,
3113 for CCD and 2650 for healthy.
Of the discriminating masses 13.3%, 9.5% and 9.3% for ICD,
CCD and healthy groups, respectively, could be assigned to
metabolic pathways using MassTRIX. However, 89.6% could not
be assigned using MassTRIX software indicating that the available
databases used for the identification of masses are yet limited by
incompleteness. Some of the unassigned masses were interesting,
such as the negative ion at mass-to-charge ration (m/z) of 229.1557
or 391.2853 (see Fig. 1B), that were characteristic for ICD patients.
Pathways with differentiating metabolites included those involved in
the metabolismand or synthesis of amino acids, fattyacids,bile acids
and arachidonic acid and these are discussed in more detail below.
We found numerous masses corresponding to metabolites within
the tyrosine metabolic pathway (Fig. 2B) that discriminated diseased
from healthy groups. For example, dopaquinone, an oxidation
product of dopa and an intermediate in the formation of melanin
from tyrosine, was more abundant (P,0.05) in CD patients (both
CCD and ICD) than in healthy individuals. L-DOPA has been
observed at elevated levels in inflamed mucosa of IBD patients [18].
There is also some evidence that polymorphisms in the dopamine
receptor D-2 play a role in CD [19]. In addition, 4-hydroxyphe-
nylacetylglycine and (Z)-4-hydroxyphenylacetaldehyde-oxime con-
tributed substantially to the separation of CCD individuals. In a
previous study 4-hydroxyphenylacetylglycine in urine was nega-
tivelycorrelated totheabundanceofFaecalibacteriumprausnitziiin
the gut [5]. We observed the same negative correlation for
healthyIndividuals, but in contrast we found higher levels of 4-
hydroxyphenylacetylglycine levels in the feces of a subset of CCD
patients with elevated F. Prausnitzii abundances previously
published from the same samples [2]. These differences could be
due to the different sample origins in the different studies; i.e. urine
compared to feces. In our previous studies and others F. prausnitzii
was more abundant in healthy individuals and those with CCD
compared to individuals with ICD [2], [20]. These results suggest
there could be a link between F. prausnitzii and the metabolite 4-
hydroxyphenylacetylglycine that warrants further study.
Increased amounts of metabolites involved in tyrosine metab-
olism coincides with earlier reports of increased transcripts of
genes involved in tyrosine metabolism in peripheral blood
mononuclear cells from CD patients [21]. However, it is not
clear what (if any) role increased tyrosine metabolism may play in
CD. Interestingly, protein tyrosine phosphatases have been
associated with autoimmune diseases [22], although such muta-
tions have not been correlated to CD.
The amino acids tryptophan and phenylalanine were also
indicative of the ICD phenotype (Table 1). The presence of
tryptophan in the feces might correspond to a subset of previously
Crohn’s Metabolomics
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tryptophan levels [23]. Interestingly, one ICD individual did not
have detectable levels of tryptophan or phenylalanine, and this
individual also had the lowest abundance of mucosal E. coli [2],
compared to the other ICD individuals. Although other organisms
could also be correlated to these metabolites, it would be of interest
to further investigate any links between E. coli abundance and
amino acids in the gut. Previous studies [24] have shown that E.
coli isolated from CD patients have pathogen-like behavior in vitro,
and may play a role in the inflammatory process. Marchesi et al.
[7] also observed increased levels of some other amino acids in
fecal samples of CD patients with active disease (ours were in
remission), but these were different amino acids than those we
found; i.e. alanine, isolueucine, leucine and lysine. The presence of
amino acids in the feces of ICD patients in general may be the
result of malabsorption resulting from the shortening of the small
bowel or due to subclinical inflammation, or conversely the result
of secretion into the bowel. Regardless of the underlying
mechanism, these results suggest that a special consideration of
amino acid balance should be made for patients with active disease
as well as those in remission.
Many masses corresponding to metabolites within the bile acid
biosynthesis pathway contributed to the segregation of disease
phenotypes. In particular, the mass corresponding to glycocholate
was prevalent in a majority of individuals with CD (Table 1), but
not detected in healthy individuals. Masses corresponding to
taurocholate, 3a,7 a,1 2 a-trihydroxy-5b-cholanate and cheno-
deoxyglycocholate were also particularly high (P,0.001) in ICD
Figure 1. (A) Score and loading scatter plot of PLS analysis (Q
2(cum)=0.96, R
2(Y)=0.95). (blueN=ICD, redN=CCD and greenN=Healthy).
The masses with the highest regression coefficients were considered as discriminant. Coordinates on the figure axes are 610
8. (B) Example of a
differentiating metabolite for ICD (assigned at m/z of 391.2853) that is up regulated in the ICD group but the structure is unknown. (C) Mass at m/z of
407.2802 corresponding to 3a,7 a,o r1 2 a-trihydroxy-5b-cholanate withinthe bileacid biosynthesis pathway. The intensitiesin B andC were normalized.
doi:10.1371/journal.pone.0006386.g001
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model; (B) Tyrosine metabolism pathway, the red metabolites were identified and present in the ICD group. Green shading refers to enzymes that
were annotated in Bacteroides vulgatus.
doi:10.1371/journal.pone.0006386.g002
Crohn’s Metabolomics
PLoS ONE | www.plosone.org 5 July 2009 | Volume 4 | Issue 7 | e6386patients (Table 1). The majority of bile acids are reabsorbed in the
distal ileum, largely accomplished by an apical sodium dependent
bile acid transporter, and thus ileal resection could explain the
reduced bile acid absorption in ICD patients. However, only 1 of
the 4 CCD patients with glycocholate in the feces had undergone
resection surgery. This is consistent with the finding that patients
with and without ileal resection have altered bile composition [25].
Increased bile in the feces may indicate that although these
subjects were in remission they were nevertheless experiencing
sub-clinical inflammation as bile acid absorption has been shown
to be inhibited by inflammation [26], or increased mucosal
permeability [27]. A detrimental feedback loop could be created
where inflammation results in reduced bile absorption, therefore
increased bile in the lumen, which in turn causes increased
inflammation.
Masses corresponding to both saturated and unsaturated fatty
acids, including oleic acid, stearic acid, palmitic acid, 6Z-, 9Z-, and
12Z-octadecatrienoic acid, linoleic acid and arachadonic acid,
were also higher in patients with ICD compared to the other
groups (Table 1). Fernandez Baneres et al. [28] previously reported
elevated levels of arachidonic acid and linoleic acid in colonic
mucosa of CD patients, consistent with our results from fecal
samples, but they also found reduced amounts of oleic acid in the
mucosa, contrary to the increased levels we observed.
Arachidonic acid is particularly interesting because it is known
to mediate inflammation and the functioning of several organs and
systems either directly or upon its conversion into eicosanoids.
Arachidonic acid has previously been shown to increase the
expression of the intracellular adhesion molecule (ICAM)-1, which
is involved in the recruitment of leukocytes, suggesting another
role of this molecule [29]. Linoleic acid and arachidonic acid are
also essential for the synthesis of prostaglandins (PG), which are
important immune signaling molecules. However, in our study the
increased abundances of these fatty acids did not correspond to
levels of PG (see below) and further studies are necessary to
determine their possible links and correlations to CD.
Masses corresponding to PG and their breakdown products
including PGF2a and 2,3-dinor-8-iso-PGF2a, thromboxane/6-
Keto-PGF1a/PGI2 and PGE2 were more prevalent in healthy
individuals (including the young group) than those with CCD and
ICD (Table 1). The role of PG as immune signaling molecules is
particularly interesting as CD is associated with disregulated
immune function. CD-associated alleles have recently been
negatively correlated to quantitative expression levels of prosta-
glandin receptor EP4 (PTGER4) [30] and PTGER4 knockout
mice experience more severe colitis in the dextran sodium sulfate
model of colitis. The reduced levels of PGs that we observed may
reflect a reduced absorption of their precursors, arachidonic acid
Table 1. Identified fecal metabolites that contribute to the discrimination of disease phenotypes.














* 5 133363 b 1 2616539 b 4 .015
4-hydroxyphenyl-acetylglycine 8699313 a
* 50 b 0 140068 b 1 .012
(Z)/4/hydroxyphenyl-acetaldehyde-oxime 502918 a
* 40 b 00 b 0 .006
Amino acids Tyrosine 335531 b 3 86251 b 1 1441491 a
* 6 .001
Tryptophan 208343 b 2 0 0 1087303 a
* 5 .001
Phenylalanine 0 b 0 0 0 1405997 a
* 5 .001
Bile acid metabolism Glycocholate 715048 b
* 4 0 0 1847470 a
* 5 .001
Taurocholate 312872 b 2 179560 b 2 14227172 a
* 5 .002




335746 b 2 83591 b 1 1200688 a
* 5 .002
Fatty acid biosynthesis Oleic acid 451036 b 2 580092 b 3 5745324 a
* 5 .010
Stearic acid 661070 b 3 687268 b 5 2658962 a
* 5 .021
Palmitic acid 357430 b 2 184491 b 2 2476141 a
* 5 .006
arachidonic acid 0 b 00 b 0 715296 a
* 3 .004
octadecatrienoic acid 0 b 00 b 0 568143 a
* 3 .005
linoleic acid 920810 b 3 778285 b 4 5202328 a
* 5 .022
Arachidonic acid prostaglandin F2a 607077 4 1400944
* 9 977053 4 .142
metabolism/prostaglandins 2,3-dinor-8-iso-prostaglandin F2a 4002093 8 4048724
* 10 1918427 6 .093
prostaglandin F1a 1216394 b 7 2482457a
* 10 812282 b 4 .017
prostaglandin E2a 1726834 8 2662085




* 4 513000 b 4 3632083 a
* 6 .001
*Indicates the group discriminated by the given metabolite in PLS-DA; n, indicates number out of the total number of individuals in each disease category.
1Mean, refers to the mean amount (daltons) of the metabolite detected in all individuals within a given disease category.
P values indicate a significant difference between groups based on Anova; different subscript letters indicate groups that differed significantly (,.05).
doi:10.1371/journal.pone.0006386.t001
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prostaglandin levels in CD patients that were in remission PG
particularly PGE2, have been observed to be more abundant in
patients with active CD [31]. This is consistent with the fact that
PGE2 is proinflammatory, acting through the EP-2/4 receptor on
dendritic cells inducing the expression of IL-23 resulting in a
TH17 phenotype associated with CD [31]. Therefore, reduced PG
levels in CD patients in remission observed here may make them
susceptible to relapse, although elevated levels during active
disease could be a cause of tissue damage. Intriguingly, 3-(4-
hydroxyphenyl)-propionic acid, that has previously been shown to
suppress PGE2 production [32], was particularly elevated in a
subset of CCD and ICD individuals.
Manhattan distances were calculated from the metabolic
profiles of all individuals to determine whether the gut metabo-
lomes of twins were more similar to each other than to unrelated
individuals. The inter-twin similarity (mean6SE) of healthy twins
(0.51360.035) and concordant twins (0.43160.070) was greater
(P,0.001) than that of discordant twins (0.27660.048). This
coincides with the reduced similarity of microbial profiles
previously observed in the discordant twins [17]. A correlation
between the metabolic and microbial distance matrices (r=0.348,
P,0.001) coincides with findings from Li et al. [5] correlating fecal
microbial profiles to urinary metabolites, indicating a contribution
of bacteria to overall metabolic profiles in the human host. We
observed a stronger correlation between metabolic and microbial
similarities when making within twin comparisons (r=0.748,
P,0.001) strengthening the hypothesis that genetics plays a role in
the formation and maintenance of the intestinal microbiome
(Fig. 3). The most striking observation from the cluster analysis
(Fig. 3) was the similar division of clusters according to the disease
phenotype for both the microbial and metabolite data reinforcing
the link between microbial community structure, function and
disease.
Subsequently, we also correlated the metabolomes to the relative
abundances of specific bacterial populations within the same
samples. We used a PLS model with relative abundances of specific
microbial populations as the Y matrix and the m/z data as the
independent variables to correlate the MS data to microbes and
disease status (Fig. 4A). The masses were correlated to predefined
Figure 3. Similarity plot (using Jaccard’s index) of (A) microbial composition based on binary T-RFLP data and (B) ICR-FT/MS data,
respectively, from fecal samples of individuals with ICD (blue), CCD (red) and healthy individuals (green). Individuals were numbered
according to Table S1, and as previously defined (11). Boxes indicate twin pairs that share the most similar metabolic and microbial profiles. Note:
metaproteome data from the same fecal samples for individuals 6a and 6b have recently been published [33].
doi:10.1371/journal.pone.0006386.g003
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abundant depending on the disease phenotype of the host [2], [17].
For example, Bacteroides vulgatus (BV), B. ovatus (BO) and E. coli (EC)
werepresent at significantly higherlevelsinthe ICDgroup, whereas
F. prausnitzii (FP) and B. uniformis (BU) were more abundant in the
healthy and the CCD groups. The 10 masses with the highest
regression coefficient value for each of the 5 bacteria indicated
above were assigned in MassTRIX (Table S2). The correlation
Figure 4. PLS loading plot (A) where bacterial abundance defined the Y matrix and ICR-FT/MS data were plotted as predictors of
differentiating bacteria based on their regression coefficients. Masses with the greatest regression coefficients for specific bacterial
populations that were more abundant [B. ovatus (BO), B. vulgatus (BV), and Escherichia coli (EC)] and less abundant [Faecalibacterium prausnitzii (FP)
and Bacteroides uniformis (BU)] in the feces of individuals with ileal Crohn’s disease (ICD) compared to individuals with colonic Crohn’s disease (CCD)
and healthy (H) individuals are identified in the heat plot (B). The heat plot indicates the abundance of masses, the predicted metabolite, the bacteria
that were positively correlated to that metabolite and whether the metabolite was positively (+) or negatively (2) associated with ICD. The clustering
on the x-axis is according to disease and that on the y-axis is according to the relative abundances of the same bacterial populations selected in (A)
and corresponding abbreviations are given on the first column to the right of the heat plot. Individuals on the x-axis are coded according to [17].
Each cell is colored based on the detected level of the predicted metabolite.
doi:10.1371/journal.pone.0006386.g004
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these data were expressed in a heat map for visualization of the data
clustering (Fig. 4B). In this analysis the individuals clustered mainly
into two groups: 1) ICD and 2) healthy + CCD, similar to what we
found with the PCA plot of the original metabolite data (Figure S1).
Bacteria that were more abundant in individuals withICD (BV, BO
and EC) were those that were most strongly correlated to bile acids,
including taurocholic and cholic acids, and fatty acids, including
stearic, and docosapentanoic acids. Conversely, bacteria that were
more abundant in healthy or CD phenotypes (BU and FP) were
correlated to phospholipids and flavin mononucleotide (FMN). The
correlation of these metabolites to specific bacterial groups merits
furtherattention,such asthecausalityofthe relationshipbetweenE.
coliand elevated levelsof taurocholic acid.It should be kept in mind,
however, thatotherbacteriathat weren’t specificallyincludedinthis
screening could be contributing to the metabolite profiles seen.
In summary, this study demonstrates the potential of metabo-
lomics to provide a means to differentiate disease phenotypes and to
give newinsights into theetiology of Crohn’s disease. Ourstudyalso
emphasizes the importance of metabolites produced by the gut
microbiota for a healthy gut environment. The analysis procedure
was rapid to perform and resulted in highly accurate mass data.
Several masses were found that differentiated healthy, ICD and
CCD individuals. Interestingly, the similarity of metabolite profiles
in healthy monozygotic twin pairs underscores the importance of
geneticsindeterminingthenatureofthegutenvironment,including
the bacterial species that are most dominant and the metabolites
they produce. Further investigation of those masses that were
important in differentiation of disease phenotypes, but that could
not be assigned to structures, will be an aim for the future using
structure identification tools involving hyphenated multidimension-
al separation, spectrometric and spectroscopic tools.
Our results pinpoint significant differences in the types and
number of metabolites within specific pathways, including tyrosine
and phenylalanine metabolism and bile acid and fatty acid
biosynthesis that could be of key importance for different Crohn’s
Disease etiologies. Thus, not only the identified individual
metabolites, but also the pathways they belong to, could lead to
future therapeutic biomarkers or drug targets.
Supporting Information
Figure S1 Principal component analysis (PCA) scatter plot of
fecal metabolites from healthy adults (green filled squares), healthy
young (green filled circles), individuals with ileal Crohn’s disease
(blue), or colonic Crohn’s disease (red). The total variance
absorbed was 23% and the Eigen values are 6.7 for the first
component and 3.38 for the second component.
Found at: doi:10.1371/journal.pone.0006386.s001 (0.54 MB TIF)
Table S1 Clinical data for twins and responses to a question-
naire
Found at: doi:10.1371/journal.pone.0006386.s002 (0.20 MB
DOC)
Table S2 Masses defined through the analysis presented in 5a)
and assigned in MassTRIX
Found at: doi:10.1371/journal.pone.0006386.s003 (0.11 MB
DOC)
Acknowledgments
We thank Juha Apajalahti (Alimetrics, Finland) for preparation of the fecal
water samples.
Author Contributions
Conceived and designed the experiments: JJ PSK. Performed the
experiments: AF JH CT PSK. Analyzed the data: JJ BW ML AF JD
PSK. Contributed reagents/materials/analysis tools: JJ AF JD JH CT
PSK. Wrote the paper: JJ BW ML AF JD JH CT PSK. Initiator to this
metabolomic study: PSK JJ.
References
1. Sartor RB (2006) Mechanisms of disease: Pathogenesis of Crohn’s disease and
ulcerative colitis. Nature Clin Practice Gastroenterol & Hepatology 3: 390–407.
2. Willing B, Halfvarson J, Dicksved J, Rosenquist M, Jarnerot G, et al. (2009)
Twin studies reveal specific imbalances in the mucosa-associated microbiota of
patients with ileal Crohn’s disease. Inflamm Bowel Dis 15: 653–660.
3. Nicholson JK, Holmes E, Wilson ID (2005) Gut microorganisms, mammalian
metabolism and personalized health care. Nature Rev Microbiol 3: 431–438.
4. Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, et al. (2009)
Metabolomics analysis reveals large effects of gut microflora on mammalian
blood metabolites. Proc Natl Acad Sci U S A 106: 3698–3703.
5. Li M, Wang B, Zhang M, Rantalainen M, Wang S, et al. (2008) Symbiotic gut
microbes modulate human metabolic phenotypes. Proc Natl Acad Sci U S A
105: 2117–2122.
6. Holmes E, Loo RL, Stamler J, Bictash M, Yap IKS http://www.nature.com/
nature/journal/v453/n7193/full/nature06882.html - a1http://www.nature.
com/nature/journal/v453/n7193/full/nature06882.html- a3et al, Human
metabolic phenotype diversity and its association with diet and blood pressure.
Nature 453: 396–400.
7. Marchesi JR, Holmes H, Khan F, Kochhar S, Scanlan P, et al. (2007) Rapid and
noninvasive metabonomic characterization of inflammatory bowel disease.
J Proteome Res 6: 546–551.
8. Saric J, Wang Y, Li J, Coen M, Utzinger J, et al. (2008) Species variation in the
fecal metabolome gives insight into differential gastrointestinal function.
J Proteome Res 7: 352–360.
9. Rossello-Mora R, Lucio M, Pen ˜a A, Brito-Echeverrı ´aJ ,L o ´pez-Lo ´pez A, et al.
(2008) Metabolic evidence for biogeographic isolation of the extremophilic
bacterium Salinibacter ruber. ISME J 2: 242–253.
10. Chen J, Zhao X, Fritsche J, Yin P, Schmitt-Kopplin P, et al. (2008) Practical
approach for the identification and isomer elucidation of biomarkers detected in
a metabonomic study for the discovery of individuals at risk for diabetes by
integrating the chromatographic and mass spectrometric information. Anal
Chem 80: 1280–1289.
11. Halfvarson J, Bodin L, Tysk C, Lindberg E, Ja ¨rnerot G (2003) Inflammatory
bowel disease in a Swedish twin cohort: A long-term follow-up of concordance
and clinical characteristics. Gastroenterol 124: 1767–1773.
12. Dicksved J, Halfvarson J, Rosenquist M, Ja ¨rnerot G, Tysk C, et al. (2008)
Molecular analysis of the gut microbiota of identical twins with Crohn’s disease.
ISME J 2: 716–727.
13. Harvey RF, Bradshaw JM (1980) A simple index of Crohn’s-disease activity.
Lancet 315: 514.
14. Rutgeerts P, Goboes K, Peeters M, Hiele M, et al. (1991) Effect of faecal stream
diversion on recurrence of Crohn’s disease in the neoterminal ileum. Lancet 338:
771–774.
15. Suhre K, Schmitt-Kopplin P (2008) Masstrix: Mass translator into pathways.
Nucleic Acids Research 36: W481–W484.
16. Legendre P, Legendre L (1998) Numerical Ecology. Amsterdam, Elsevier
Science 132: 303–304.
17. Dicksved J, Halfvarson J, Rosenquist M, Ja ¨rnerot G, Tysk C, et al. (2008) JK
Molecular analysis of the gut microbiota of identical twins with Crohn’s disease.
ISME J 2: 716–727.
18. Magro F, Vieira-Coelho MA, Fraga S, Serra ˜o MP, Veloso FT, et al. (2002)
Impaired synthesis or cellular storage of norepinephrine, dopamine and 5-
hydroxytryptamine in human inflammatory bowl disease. Dig Dis Sci 47:
216–224.
19. Magro F, Cunha E, Araujo F, Meireles E, Pereira P, et al. (2006) Dopamine D2
receptor polymorphisms in inflammatory bowel disease and the refractory
response to treatment. Dig Dis Sci 51: 2039–2044.
20. Sokol H, Pigneur B, Watterlot L, Lakhdari O, et al. (2008) Faecalibacterium
prausnitzii is an anti-inflammatory commensal bacterium identified by gut
microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105:
16731–16736.
21. Burczynski ME, Peterson RL, Twine NC, Zuberek KA, Brodeur BJ (2006)
Molecular classification of crohn’s disease and ulcerative colitis patients using
transcriptional profiles in peripheral blood mononuclear cells. J Mol Diag 8:
51–61.
22. Vang T, Miletic AV, Arimura Y, Tautz L, et al. (2008) Protein tyrosine
phosphatases in autoimmunity. Ann Rev Immunology 26: 29–55.
23. Beeken WL (1976) Serum tryptophan in Crohn’s-disease. Scand J Gastroenterol
11: 735–740.
Crohn’s Metabolomics
PLoS ONE | www.plosone.org 9 July 2009 | Volume 4 | Issue 7 | e638624. Baumgart M, Dogan B, Rishniw M, Weitzman G, Bosworth B, et al. (2007)
Culture independent analysis of ileal mucosa reveals a selective increase in
invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales
in Crohn’s disease involving the ileum. ISME J 1: 403–418.
25. Lapidus A, Akerlund JE, Einarsson C (2006) Gallbladder bile composition in
patients with crohn’s disease. World J Gastroenterol 12: 70–74.
26. Chen F, Ma L, Sartor RB, Li F, Xiong H, et al. (2002) Inflammatory-mediated
repression of the rat ileal sodium-dependent bile acid transporter by c-fos
nuclear translocation. Gastroenterol 123: 2005–2016.
27. Lowes S, Simmons NL (2001) Human intestinal cell monolayers are
preferentially sensitive to disruption of barrier function from basolateral
exposure to cholic acid: Correlation with membrane transport and transepithe-
lial secretion. Pflugers Archiv-European J Physiology 443: 265–273.
28. Ferna ´ndez-Ban ˜ares F, Esteve-Comas M, Man ˜e ´ J, Navarro E, Bertra ´n X, et al.
(1997) Changes in mucosal fatty acid profile in inflammatory bowel disease and
in experimental colitis: A common response to bowel inflammation. Clinical
Nutrition 16: 177–183.
29. Ramakers JD, Mensink RP, Schaart G, Plat J (2007) Arachidonic acid but not
eicosapentaenoic acid (epa) and oleic acid activates nf-kappa b and elevates
icam-1 expression in caco-2 cells. Lipids 42: 687–698.
30. Libioulle C, Louis E, Hansoul S, Sandor C, Farnir F, et al. (2007) Novel Crohn
disease locus identified by genome-wide association maps to a gene desert on
5p13.1 and modulates expression of PTGER4. Plos Genet 3: e58.
31. Sheibanie AF, Yen JH, Khayrullina T, Emig F, Zhang M, et al. (2007) The
Proinflammatory Effect of Prostaglandin E2 in Experimental Inflammatory
Bowel Disease Is Mediated through the IL-23RIL-17 Axis. J Immunolog 178:
8138–8147.
32. Karlsson PC, Huss U, Jenner A, Halliwell B, Bohlin L, et al. (2005) Human
Fecal Water Inhibits COX-2 in Colonic HT-29 Cells: Role of Phenolic
Compounds. J Nutr 135: 2343–2349.
33. Verberkmoes NC, Russell AL, Shah M, Godzik A, Rosenquist M, et al. (2009)
Shotgun metaproteomics of the human distal gut microbiota. ISME J 3:
179–189.
Crohn’s Metabolomics
PLoS ONE | www.plosone.org 10 July 2009 | Volume 4 | Issue 7 | e6386